drugset / Trial / NCT03722433

Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication

NCT03722433

Phase 4 Unknown 200 enrolled National Taiwan University Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The investigators aimed to assess the effect of probiotic supplementation with Vigiis 101-LAB during H. pylori eradication therapy with 14-day sequential therapy in the reduction of adverse effects and the restoration of the dysbiosis.

Timeline

Start
2018-08-29
Primary completion
2019-07-31
Completion
2020-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Vigiis 101-LAB Other / unclassified 1 unknown
Background Amoxicillin Other / unclassified
Background Clarithromycin Small molecule
Background Esomeprazole Small molecule
Background Metronidazole Small molecule